Category - Developments

Developments

Spartan Bioscience launches Legionnaires DNA test

Closely-held Spartan Bioscience has launched the Spartan Legionella Detection System, the first on-site DNA test for Legionella that can detect and quantify Legionella bacteria in 45 minutes. The system consists of a...

November 27, 2017

Developments

EMA accepts Titan’s Probuphine marketing application for review

The European Medicines Agency has accepted for review Titan Pharmaceuticals’ (NASDAQ:TTNP) marketing authorization application (MAA) for Probuphine. The acceptance marks the beginning of the EMA’s regulatory...

November 27, 2017

Developments

BioLight agrees to sell stake in IOPtima

BioLight Life Sciences (TASE:BOLT) and other shareholders of its subsidiary, IOPtima, entered into a binding agreement for the investment and acquisition in stages of IOPtima by Chengdu Kanghong Pharmaceutical Group of...

November 21, 2017

Developments

BiondVax, NIAID in Phase 2 trial of universal flu vaccine

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) signed a clinical trial agreement for a Phase 2 clinical trial with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The study is designed to evaluate...

November 20, 2017

Developments

Oramed to conduct NASH study with oral insulin capsule

Oramed Pharmaceuticals (NASDAQ:ORMP) received approval from Israel’s Ministry of Health to initiate an exploratory clinical study of its oral insulin capsule, ORMD-0801, in patients with nonalcoholic...

November 14, 2017

Developments

Theralase researcher discovers potent anti-cancer drugs

Theralase Technologies (OTCQX:TLTFF; TSXV:TLT) recently identified a new platform of super potent anti-cancer drugs, or PDCs, discovered by Dr. Sherri McFarland, Professor, Department of Chemistry and Biochemistry...

November 14, 2017

Developments

Cellect CEO to be keynote speaker at regenerative medicine conference

Cellect Biotechnology (NASDAQ, TASE:APOP) CEO, Dr. Shai Yarkoni, was selected to provide the keynote presentation at the 11th World Congress of Regenerative Medicine and Stem Cell Technologies in Singapore. The event is...

November 10, 2017

Developments

Profound Medical expands use of TULSA-PRO to BPH

Profound Medical (OTCQX:PRFMF; TSXV:PRN) announced that benign prostatic hyperplasia (BPH) treatments utilizing TULSA-PRO are now being successfully conducted in Germany. BPH is a non-cancerous enlargement of the...

November 6, 2017

Developments

Flex Pharma reports positive Phase 2 ALS cramping data

Flex Pharma (NASDAQ:FLKS) announced positive topline data for FLX-787 from its placebo-controlled, crossover Australian trial in amyotrophic lateral sclerosis (ALS) patients with frequent muscle cramps. The study was...

November 6, 2017

Developments

Oramed gets EU notice of broad patent claims for oral proteins

The European Patent Office has issued to Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) a notice of intent to grant a patent for broader claims for its invention titled, “Methods and Compositions for Oral Administration of...

October 31, 2017

Category - Developments

Subscribe